“One significant challenge was getting stakeholders to appreciate the value of couple testing as an HIV-prevention strategy. Through aggressive advocacy we were able to get couple HIV testing into mainstream HIV prevention efforts on a national level.”
- Patrick Ndase
The Mashi study is a clinical trial investigating novel approaches in the prevention of mother-to-child-transmission of HIV (PMTCT) including maternal health, infant health outcomes, safe feeding strategies, as well as optimal anti-retroviral drug interventions
Monitor the rates and outcomes of diarrheal and respiratory diseases among infants born to HIV-positive mothers, as compared to infants born to HIV- negative mothers, and the association between infant outcomes and breastfeeding.
Determine the response to nevirapine containing HAART among women who have previously taken single-dose nevirapine (NVP) for the prevention of MTCT.
A Randomized Trial of Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine to Prevent Mother-to-Child HIV Transmission among Breastfeeding Women with CD4 Counts > 200 cells/mm3 in Botswana. Determine the optimal HAART regimen to prevent mother-to-child HIV transmission (MTCT) among 700 HIV-infected breastfeeding women in Botswana
Determine if HSV-2 co-infection influences how often and how much HIV virus is present in the genital tract among women taking ART.
Determine if giving the medication acyclovir to HIV infected individuals also infected with the virus that causes genital herpes (HSV-2), reduces the risk of these individuals transmitting HIV to their uninfected sexual partner.
Determine if women who have taken nevirapine (NVP) to PMTCT of HIV (and who may therefore have developed virus that is resistant to NVP) will have a better response to antiretroviral therapy that includes a protease inhibitor rather than NVP.
The primary objectives of the study include (1) characterizing the development of drug resistance, (2) evaluating the safety, tolerability, and effectiveness of these combinations, and (3) comparing two adherence arms to determine the best long-term adherence strategies.
This Study is a prospective observational cohort study evaluating long-term HAART outcomes (immunologic, virologic, and clinical) among all eligible and consenting former Adult Antiretroviral Treatment and Drug Resistance (“Tshepo”) study participants. Anticipated duration is 18 months.
Pilot Study Evaluating the Efficacy and Tolerability of Tenofovir and Emtricitabine (Truvada™) as the Nucleoside Reverse Transcriptase Inhibitor (NRTI) Backbone As First-Line HAART for Adults In Botswana.
Determine if combined supplementation of multivitamins and selenium can further improve immune function, delay disease progression to AIDS or mortality, delay time to initiation of anti-retroviral therapy (ART) and avert or reduce side effects associated with ART in HIV infected adults in Botswana.
Investigating the immune characteristics of individuals who are newly infected with HIV.
Evaluate the cost implications of the Botswana National ARV Therapy Programme. Included is the Botsogo Study which examines the natural history of HIV-1C disease progression to describe the CD4 cell decline and associated HIV related illnesses over time in HIV infected individuals.
Investigating current health and HIV/AIDS spending, as well as projecting future resource gaps in Botswana.
Investigating the cost effectiveness and cost-savings of varying models of clinical healthcare delivery and laboratory monitoring.
As part of the International Maternal Paediatric Adolescent AIDS Clinical Trials (IMPAACT) network, the Masea Study is looking at the efficacy of isoniazid in preventing tuberculosis infection among infants with perinatal exposure to HIV.
BHP’s HIV Vaccine Initiative developed the infrastructure to conduct HIV vaccine trials in Botswana, including establishing a clinical trial site, laboratory facilities, assembling a scientific and clinical research team and worked with communities to gain support for HIV vaccine research. Both Phase I trials evaluate the safety and immunogenicity of the HIV vaccine experimental product.